Ultomiris

News

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

News

Ultomiris fail mars AZ's strong Q2 results

AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.

News

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

At second ask, FDA clears AZ’s Ultomiris for NMOSD

AstraZeneca’s Ultomiris has been approved by the FDA to treat rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), six months after an earlier applicati

News

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuri

News

FDA blocks new use for AstraZeneca's Ultomiris

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is.

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Ultomiris fail mars AZ's strong Q2 results

ASH: Regeneron plays its PNH hand

At second ask, FDA clears AZ’s Ultomiris for NMOSD

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

FDA blocks new use for AstraZeneca's Ultomiris

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

Ultomiris

Editor's Picks